Cargando…

Treatment with anti‐neonatal Fc receptor (FcRn) antibody ameliorates experimental epidermolysis bullosa acquisita in mice

BACKGROUND AND PURPOSE: Pemphigus and pemphigoid diseases are characterized and caused predominantly by IgG autoantibodies targeting structural proteins of the skin. Their current treatment relies on general and prolonged immunosuppression that causes severe adverse events, including death. Hence, n...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kasprick, Anika, Hofrichter, Maxi, Smith, Bryan, Ward, Penelope, Bieber, Katja, Shock, Anthony, Ludwig, Ralf J., Schmidt, Enno
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Research Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7174883/ https://www.ncbi.nlm.nih.gov/pubmed/31975370 http://dx.doi.org/10.1111/bph.14986

Ejemplares similares

Fcγ Receptor IIB Controls Skin Inflammation in an Active Model of Epidermolysis Bullosa Acquisita
por: Kovacs, Balint, et al.
Publicado: (2020)

Epidermolysis Bullosa Acquisita: The 2019 Update
por: Koga, Hiroshi, et al.
Publicado: (2019)

T cells mediate autoantibody-induced cutaneous inflammation and blistering in epidermolysis bullosa acquisita
por: Bieber, Katja, et al.
Publicado: (2016)

Therapeutic Effect of a Novel Phosphatidylinositol-3-Kinase δ Inhibitor in Experimental Epidermolysis Bullosa Acquisita
por: Koga, Hiroshi, et al.
Publicado: (2018)

Characterization of the Rabbit Neonatal Fc Receptor (FcRn) and Analyzing the Immunophenotype of the Transgenic Rabbits That Overexpresses FcRn
por: Catunda Lemos, Ana Paula, et al.
Publicado: (2012)

Epidermolysis bullosa acquisita()
por: Miyamoto, Denise, et al.
Publicado: (2022)

The Neonatal Fc Receptor (FcRn): A Misnomer?
por: Pyzik, Michal, et al.
Publicado: (2019)

The neonatal Fc receptor in cancer FcRn in cancer
por: Cadena Castaneda, Diana, et al.
Publicado: (2020)

The Role of FcRn in Antigen Presentation
por: Baker, Kristi, et al.
Publicado: (2014)

Whole-Genome Expression Profiling in Skin Reveals SYK As a Key Regulator of Inflammation in Experimental Epidermolysis Bullosa Acquisita
por: Samavedam, Unni K., et al.
Publicado: (2018)

Roles of FcRn in Antigen-Presenting Cells during Autoimmunity and a Clinical Evaluation of Efgartigimod as an FcRn Blocker
por: Zhou, Yihan, et al.
Publicado: (2023)

Pathological Relevance of Anti-Hsp70 IgG Autoantibodies in Epidermolysis Bullosa Acquisita
por: Tukaj, Stefan, et al.
Publicado: (2022)

FcRn is mother’s milk to allergen tolerance
por: Lambrecht, Bart N.
Publicado: (2018)

In Translation: FcRn across the Therapeutic Spectrum
por: Qi, Timothy, et al.
Publicado: (2021)

Megalin Orchestrates FcRn Endocytosis and Trafficking
por: Dahlke, Eileen, et al.
Publicado: (2022)

Selection of bispecific antibodies with optimal developability using FcRn‑Ph‑HPLC as an optimized FcRn affinity chromatography method
por: Müller, Thomas, et al.
Publicado: (2023)

Clinical Presentation, Pathogenesis, Diagnosis, and Treatment of Epidermolysis Bullosa Acquisita
por: Ludwig, Ralf J.
Publicado: (2013)

FcRn Overexpression Expands Diversity of the Humoral Immune Response in bFcRn Transgenic Mice
por: Szikora, Bence, et al.
Publicado: (2020)

FcRN receptor antagonists in the management of myasthenia gravis
por: Bhandari, Vinaya, et al.
Publicado: (2023)

Therapeutic effects of Fc gamma RIV inhibition are mediated by selectively blocking immune complex-induced neutrophil activation in epidermolysis bullosa acquisita
por: Haeger, Swantje C., et al.
Publicado: (2022)

Risk factors and sequelae of epidermolysis bullosa acquisita: A propensity-matched global study in 1,344 patients
por: Kridin, Khalaf, et al.
Publicado: (2023)

The importance of FcRn in neuro-immunotherapies: From IgG catabolism, FCGRT gene polymorphisms, IVIg dosing and efficiency to specific FcRn inhibitors
por: Dalakas, Marinos C., et al.
Publicado: (2021)

Epidermolysis bullosa acquisita: current diagnosis and therapy
por: Mehren, Christine R., et al.
Publicado: (2011)

Epidermolysis Bullosa Acquisita: A Case Report
por: Kumetz, Erik A., et al.
Publicado: (2020)

Epidermolysis Bullosa Acquisita—Current and Emerging Treatments
por: Tešanović Perković, Deša, et al.
Publicado: (2023)

Pharmacokinetic Models for FcRn-Mediated IgG Disposition
por: Xiao, Jim J.
Publicado: (2012)

Cell surface dynamics and cellular distribution of endogenous FcRn
por: D’Hooghe, Lena, et al.
Publicado: (2017)

Targeting FcRn for immunomodulation: Benefits, risks, and practical considerations
por: Peter, Hans-Hartmut, et al.
Publicado: (2020)

Human IgE does not bind to human FcRn
por: Brinkhaus, Maximilian, et al.
Publicado: (2022)

Topical Application of the PI3Kβ-Selective Small Molecule Inhibitor TGX-221 Is an Effective Treatment Option for Experimental Epidermolysis Bullosa Acquisita
por: Zillikens, Hannah, et al.
Publicado: (2021)

The Fab region of IgG impairs the internalization pathway of FcRn upon Fc engagement
por: Brinkhaus, Maximilian, et al.
Publicado: (2022)

Harnessing Fc/FcRn Affinity Data from Patents with Different Machine Learning Methods
por: Dumet, Christophe, et al.
Publicado: (2023)

Pharmacokinetic‐pharmacodynamic modelling of the anti‐FcRn monoclonal antibody rozanolixizumab: Translation from preclinical stages to the clinic
por: Lledo‐Garcia, Rocio, et al.
Publicado: (2021)

Metabolite analysis distinguishes between mice with epidermolysis bullosa acquisita and healthy mice
por: Schönig, Sarah, et al.
Publicado: (2013)

Epidermolysis bullosa acquisita: an uncommon cause of esophageal stricture
por: Figueredo, Carlos, et al.
Publicado: (2021)

Epidermolysis Bullosa Acquisita: A Report of Four Cases
por: De, Abhishek, et al.
Publicado: (2022)

FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye
por: Kim, Hyuncheol, et al.
Publicado: (2009)

Abundant Intracellular IgG in Enterocytes and Endoderm Lacking FcRn
por: Mohanty, Sudhasri, et al.
Publicado: (2013)

Response to “The Role of FcRn in the Pharmacokinetics of Biologics in Patients with Multiple Myeloma”
por: Xu, Xu Steven, et al.
Publicado: (2017)

FcRn Expression in Wildtype Mice, Transgenic Mice, and in Human Tissues
por: Li, Tommy, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ee4nhkgaad5f66i3prliulujtr